{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:20:52Z","timestamp":1783646452339,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2023M3A9G6057281"],"award-info":[{"award-number":["NRF-2023M3A9G6057281"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bioorg.2023.106890","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:08:58Z","timestamp":1695762538000},"page":"106890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Repurposing of conformationally-restricted cyclopentane-based AKT\u2013inhibitors leads to discovery of potential and more selective antileishmanial agents than miltefosine"],"prefix":"10.1016","volume":"141","author":[{"given":"Ahmed H.E.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Maqusood","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trong-Nhat","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hwa","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeryon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Bin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hwan","family":"No","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106890_b0005","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1007\/s00253-020-10856-w","article-title":"Recent advances and new strategies on leishmaniasis treatment","volume":"104","author":"Roatt","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.bioorg.2023.106890_b0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.pt.2006.09.004","article-title":"Leishmaniasis and poverty","volume":"22","author":"Alvar","year":"2006","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.bioorg.2023.106890_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004349","article-title":"A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies","volume":"10","author":"Akhoundi","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.bioorg.2023.106890_b0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: a review","volume":"6","author":"Torres-Guerrero","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.bioorg.2023.106890_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2016.11.012","article-title":"Leishmania infections: Molecular targets and diagnosis","volume":"57","author":"Akhoundi","year":"2017","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bioorg.2023.106890_b0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14728222.2018.1472241","article-title":"Emerging therapeutic targets for treatment of leishmaniasis","volume":"22","author":"Sundar","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2023.106890_b0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acsinfecdis.7b00244","article-title":"Genetically Validated Drug Targets in Leishmania: Current Knowledge and Future Prospects","volume":"4","author":"Jones","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bioorg.2023.106890_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005480","article-title":"The enemy within: Targeting host\u2013parasite interaction for antileishmanial drug discovery","volume":"11","author":"Lamotte","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.bioorg.2023.106890_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12639-010-0006-3","article-title":"Drug targets in Leishmania","volume":"34","author":"Chawla","year":"2010","journal-title":"J. Parasit. Dis."},{"key":"10.1016\/j.bioorg.2023.106890_b0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejmech.2019.07.030","article-title":"Repurposing mosloflavone\/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-\u03b1 MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators","volume":"180","author":"Hassan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14756366.2019.1699554","article-title":"Reprofiling of pyrimidine-based DAPK1\/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds","volume":"35","author":"Farag","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104121","article-title":"Diarylurea derivatives comprising 2,4-diarylpyrimidines: Discovery of novel potential anticancer agents via combined failed-ligands repurposing and molecular hybridization approaches","volume":"103","author":"Farag","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nbt0712-571a","article-title":"NCATS launches drug repurposing program","volume":"30","author":"Allison","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2023.106890_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2023.106890_b0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.bioorg.2023.106890_b0080","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1039\/c4md00011k","article-title":"The role of modern drug discovery in the fight against neglected and tropical diseases","volume":"5","author":"Burrows","year":"2014","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.bioorg.2023.106890_b0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art","volume":"145","author":"Charlton","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.bioorg.2023.106890_b0090","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2023.106890_b0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14756366.2019.1693704","article-title":"Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3","volume":"35","author":"Mart\u00ednez de Iturrate","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0100","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s13071-017-2379-y","article-title":"Identification of a RAC\/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis","volume":"10","author":"Varela-M","year":"2017","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.bioorg.2023.106890_b0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.actatropica.2017.10.008","article-title":"The Akt-like kinase of Leishmania panamensis: As a new molecular target for drug discovery","volume":"177","author":"Tirado-Duarte","year":"2018","journal-title":"Acta Trop."},{"key":"10.1016\/j.bioorg.2023.106890_b0110","article-title":"AKT-like kinase promotes cell survival during nutritional stress in trypanosomatids","volume":"15","author":"Mej\u00eda","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.bioorg.2023.106890_b0115","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/biom11071037","article-title":"Identification of Potential Kinase Inhibitors within the PI3K\/AKT Pathway of Leishmania Species","volume":"11","author":"Ochoa","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2023.106890_b0120","doi-asserted-by":"crossref","first-page":"e0206920","DOI":"10.1371\/journal.pone.0206920","article-title":"Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania","volume":"13","author":"Nandan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2023.106890_b0125","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ddr.21684","article-title":"Recent strategies for the development of oral medicines for the treatment of visceral leishmaniasis","volume":"81","author":"de Souza","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2023.106890_b0130","series-title":"Highlights in Bioorganic Chemistry: Methods and Applications","first-page":"48","article-title":"Conformational Restriction of Sphingolipids","author":"Kolter","year":"2004"},{"key":"10.1016\/j.bioorg.2023.106890_b0135","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.2174\/1568026619666190712205025","article-title":"The Use of Conformational Restriction in Medicinal Chemistry","volume":"19","author":"de Sena","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0140","first-page":"357","article-title":"Application of a conformational restriction strategy in drug design","volume":"51","author":"Guoli","year":"2020","journal-title":"J. China Pharm. Univ."},{"key":"10.1016\/j.bioorg.2023.106890_b0145","doi-asserted-by":"crossref","first-page":"8609","DOI":"10.1021\/acs.jmedchem.9b00972","article-title":"A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor","volume":"62","author":"Borsari","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0150","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4155\/fmc.14.50","article-title":"Conformational restriction: an effective tactic in \u2018follow-on\u2019-based drug discovery","volume":"6","author":"Fang","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0155","doi-asserted-by":"crossref","first-page":"2217695","DOI":"10.1080\/14756366.2023.2217695","article-title":"Design, synthesis, and study of novel phenethyl-based antitumor phospholipids downregulating p38 mitogen-activated protein kinase","volume":"38","author":"Hassan","year":"2023","journal-title":"J. Enzyme Inhib. Med."},{"key":"10.1016\/j.bioorg.2023.106890_b0160","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejmech.2011.11.018","article-title":"Synthesis and biological evaluation of cyclopentane-linked alkyl phosphocholines as potential anticancer agents that act by inhibiting Akt phosphorylation","volume":"47","author":"Alam","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0165","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.bmc.2013.01.010","article-title":"Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines","volume":"21","author":"Alam","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001612","article-title":"In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and SbV-Resistant Parasites","volume":"6","author":"Varela-M","year":"2012","journal-title":"PLoS Negl Trop. Dis."},{"key":"10.1016\/j.bioorg.2023.106890_b0175","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bioorg.2023.106890_b0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijpddr.2013.11.002","article-title":"Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism","volume":"4","author":"Vincent","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.bioorg.2023.106890_b0185","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12889","article-title":"Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections","volume":"20","author":"Zhang","year":"2018","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.bioorg.2023.106890_b0190","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bioorg.2018.11.040","article-title":"Antiproliferative 3-deoxysphingomyelin analogs: Design, synthesis, biological evaluation and molecular docking of pyrrolidine-based 3-deoxysphingomyelin analogs as anticancer agents","volume":"84","author":"Hassan","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0195","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1021\/jm501683w","article-title":"Absolute Quantitative 1H NMR Spectroscopy for Compound Purity Determination","volume":"57","author":"Cushman","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0200","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/ph15091058","article-title":"Design, Rational Repurposing, Synthesis, In Vitro Evaluation, Homology Modeling and In Silico Study of Sulfuretin Analogs as Potential Antileishmanial Hit Compounds","volume":"15","author":"Hassan","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2023.106890_b0205","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1080\/14756366.2021.1969385","article-title":"Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani","volume":"36","author":"Hassan","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106890_b0210","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3390\/molecules25081980","article-title":"In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei","volume":"25","author":"Phan","year":"2020","journal-title":"Molecules"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823005515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823005515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:51:01Z","timestamp":1758617461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823005515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":42,"alternative-id":["S0045206823005515"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106890","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of conformationally-restricted cyclopentane-based AKT\u2013inhibitors leads to discovery of potential and more selective antileishmanial agents than miltefosine","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106890"}}